Latest Headlines

  1. InterVenn Biosciences Partners With Aranscia To Accelerate Commercialization Of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test 1/7/2026

    InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced a partnership where Aranscia technical and laboratory resources will help to facilitate clinical workflows and expand the availability of InterVenn's flagship GlycoKnow™ Ovarian cancer diagnostic test.

  2. SOPHiA GENETICS And MD Anderson Announce Strategic Collaboration To Accelerate AI-Driven Precision Oncology 1/7/2026

    SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.

  3. Sectra Begins Implementation Of Its First Digital Pathology Project In Japan, Aiming To Improve Cancer Diagnostics And Decrease Time To Treatment 1/7/2026

    International medical technology and cybersecurity company Sectra (STO: SECT B), in collaboration with distribution partner Matsunami Glass has commenced the implementation phase of its first digital pathology project in Japan.

  4. Cardio Diagnostics, Aimil Ltd. And Dr. Lal PathLabs Limited Partner To Launch The PrecisionCHD Test In India 1/7/2026

    Cardio Diagnostics Holdings, Inc. a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories and 300+ MD pathologists in their internal network, today announced a strategic agreement to launch Cardio Diagnostics’ PrecisionCHD test for the detection and management of coronary heart disease (CHD) in India.

  5. altona Diagnostics Launches AltoStar HDV RT-PCR Kit 1.5 (CE-IVD) 1/6/2026

    altona Diagnostics GmbH announces the launch of the AltoStar HDV RT-PCR Kit 1.5 (CE-IVD), a new PCR test for the detection and quantification of hepatitis delta virus (HDV) specific RNA in human EDTA plasma and serum.

  6. PracticeQ Partners With Fullscript To Streamline Lab Testing And Improve Patient Care 1/6/2026

    PracticeQ today announced the launch of its new labs on Fullscript integration, designed to give providers a seamless way to order, track, and manage lab testing directly within their clinical workflows.

  7. New Handheld Decapper Boosts Speed And Consistency Of 48-Format Tube Handling 1/5/2026

    Azenta Life Sciences has launched the IntelliXcap M6 Semi-Automated Handheld Screw Cap Decapper, a new addition to its range of decapper / recapper instruments designed specifically for 48-format external thread screw cap tubes.

  8. Corewell Health And Quest Diagnostics Complete Laboratory Joint Venture Transaction In Michigan 1/5/2026

    Corewell Health and Quest Diagnostics (NYSE: DGX) today announced the completion of the previously announced transaction to establish a laboratory services joint venture to expand access to innovative, quality and affordable laboratory services in Michigan.

  9. WORK Medical Technology Group LTD Subsidiary Obtains Manufacturing Approval For Its AI-Automated Blood Cell Morphology Analyzer 12/29/2025

    WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that its subsidiary, Hunan Saitumofei Co., Ltd., has received manufacturing approval from the Hunan Provincial Medical Products Administration for its Class II medical device, the Artificial Intelligence (“AI”)-Automated Human Blood Cell Morphology Analyzer.

  10. Co-Diagnostics Receives Grant Of Australian Patent Covering Co-Dx PCR Platform Technologies 12/29/2025

    Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Australian Patent Office has granted Australian Patent No. AU2022270084A1, strengthening Co-Dx's intellectual property portfolio surrounding its novel Co-Dx PCR platform*.